Novel and Emerging Combination Approaches for Advanced/Metastatic RCC

Intended Audience: Oncologists, NPs, PAs, nurses, and pharmacists who care for patients with RCC

Join us for an exciting discussion by two renowned renal cell carcinoma (RCC) experts as they delve deep into the dynamic world of RCC and provide essential insights into multiple components of evidence-based, guideline-aligned care.

This on-demand video will review the latest clinical safety and efficacy data on combination approaches for frontline treatment of metastatic renal cell, along with applications of current evidence to treatment sequencing after progression on first-line therapy.

• Differentiate novel and emerging therapeutic approaches in clear cell renal cell carcinoma (RCC) based on clinical data for their safety and efficacy and placement in treatment
• Evaluate clinical data for safety and efficacy of novel and emerging combination approaches for frontline treatment of advanced/metastatic RCC
• Apply current evidence and guideline recommendations to optimize treatment sequencing after progression on first-line therapy
• Employ evidence-based strategies for managing adverse events associated with novel combination therapies

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 0.75 contact hour (which includes 0.6 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Bradley A McGregor, MD (Speaker)
  
  Consultant – Astellas, AstraZeneca, Bristol Myers Squibb for Dana Farber Cancer Institute [DFCI], Bristol-Myers Squibb, Calithera, Dendreon, Discloses payment for consulting with Bayer, EMD Serono, Eisai, Exelixis, Genentech, Janssen, Merck, Nektar, Pfizer, Seattle Genetics
  Grants / Research Support – Bristol Myers Squibb for Dana Farber Cancer Institute [DFCI], Bristol-Myers Squibb, Calithera, Exelixis, Merck, Pfizer, Seattle Genetics
  The relationships reported above are related to the following therapeutic area: Hematology-Oncology
• Brian I. Rini, MD, FASCO (Speaker)
  
  Advisory Board or Panel – Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Merck, Pfizer
  Consultant – Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Merck, Pfizer
  Grants / Research Support – Aveo, Bristol-Myers Squibb, Merck, Pfizer
  The relationships reported above are related to the following therapeutic area: Hematology-Oncology

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Stephanie Joyce, PA, MSPAS, MS, RD CNSC (Reviewer)
• Abimbola Farinde, PhD, PharmD (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.